Growth hormone-independent cardioprotective effects of hexarelin in the rat.

Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, Deghenghi R, Müller EE, Berti F

Endocrinology1 Sept 1999Cited by 100 (Europe PMC)

PMID10465272DOI10.1210/endo.140.9.6948PepBankPUB-10465272

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In hypophysectomized rats, hexarelin given for 7 days prevented the exacerbation of ischemia-reperfusion damage caused by hypophysectomy.
In plain wordsIn rats with the pituitary gland removed, hexarelin for 7 days prevented the worse heart damage after blocked and restored blood flow.
Peptide
Hexarelin
Outcome
DecreaseIschemia-reperfusion damage after hypophysectomy
Study
ratn: not reported in source
Hypophysectomized rat, explanted heart ischemia-reperfusion
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg · subcutaneous · 7 daysAs given in this study (rat).
Source sentences
Summary
Hexarelin (80 microg/kg sc), given for 7 days, prevented exacerbation of the ischemia-reperfusion damage induced by hypophysectomy.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain whether hexarelin had non-GH-mediated protective effects on the heart, we compared hexarelin and GH treatment in hypophysectomized rats.
Report a problemFND-1046527201
02AnimalAnimal study (in vivo)Efficacy outcome
In hypophysectomized rats, hexarelin prevented the increase in left ventricular end diastolic pressure.
In plain wordsIn rats with the pituitary gland removed, hexarelin prevented a rise in pressure in the heart's main chamber.
Peptide
Hexarelin
Outcome
DecreaseLeft ventricular end diastolic pressure
Study
ratn: not reported in source
Hypophysectomized rat, explanted heart ischemia-reperfusion
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg · subcutaneous · 7 daysAs given in this study (rat).
Source sentences
Summary
We also demonstrate that hexarelin prevents increases in left ventricular end diastolic pressure, coronary perfusion pressure, reactivity of the coronary vasculature to angiotensin II, and release of creatine kinase in the heart perfusate.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain whether hexarelin had non-GH-mediated protective effects on the heart, we compared hexarelin and GH treatment in hypophysectomized rats.
Report a problemFND-1046527202
03AnimalAnimal study (in vivo)Efficacy outcome
In hypophysectomized rats, hexarelin prevented the increase in coronary perfusion pressure.
In plain wordsIn rats with the pituitary gland removed, hexarelin prevented a rise in pressure in the heart's blood vessels.
Peptide
Hexarelin
Outcome
DecreaseCoronary perfusion pressure
Study
ratn: not reported in source
Hypophysectomized rat, explanted heart ischemia-reperfusion
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg · subcutaneous · 7 daysAs given in this study (rat).
Source sentences
Summary
We also demonstrate that hexarelin prevents increases in left ventricular end diastolic pressure, coronary perfusion pressure, reactivity of the coronary vasculature to angiotensin II, and release of creatine kinase in the heart perfusate.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain whether hexarelin had non-GH-mediated protective effects on the heart, we compared hexarelin and GH treatment in hypophysectomized rats.
Report a problemFND-1046527203
04AnimalAnimal study (in vivo)Efficacy outcome
In hypophysectomized rats, hexarelin prevented the increase in reactivity of the coronary vasculature to angiotensin II.
In plain wordsIn rats with the pituitary gland removed, hexarelin prevented a stronger response of heart blood vessels to angiotensin II.
Peptide
Hexarelin
Outcome
DecreaseCoronary reactivity to angiotensin II
Study
ratn: not reported in source
Hypophysectomized rat, explanted heart ischemia-reperfusion
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg · subcutaneous · 7 daysAs given in this study (rat).
Source sentences
Summary
We also demonstrate that hexarelin prevents increases in left ventricular end diastolic pressure, coronary perfusion pressure, reactivity of the coronary vasculature to angiotensin II, and release of creatine kinase in the heart perfusate.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain whether hexarelin had non-GH-mediated protective effects on the heart, we compared hexarelin and GH treatment in hypophysectomized rats.
Report a problemFND-1046527204
05AnimalAnimal study (in vivo)Efficacy outcome
In hypophysectomized rats, hexarelin prevented the increase in creatine kinase release in the heart perfusate.
In plain wordsIn rats with the pituitary gland removed, hexarelin prevented a rise in a marker of heart muscle damage.
Peptide
Hexarelin
Outcome
DecreaseCreatine kinase release in heart perfusate
Study
ratn: not reported in source
Hypophysectomized rat, explanted heart ischemia-reperfusion
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg · subcutaneous · 7 daysAs given in this study (rat).
Source sentences
Summary
We also demonstrate that hexarelin prevents increases in left ventricular end diastolic pressure, coronary perfusion pressure, reactivity of the coronary vasculature to angiotensin II, and release of creatine kinase in the heart perfusate.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain whether hexarelin had non-GH-mediated protective effects on the heart, we compared hexarelin and GH treatment in hypophysectomized rats.
Report a problemFND-1046527205
06AnimalAnimal study (in vivo)Efficacy outcome
In hypophysectomized rats, hexarelin prevented the fall in prostacyclin release from the heart.
In plain wordsIn rats with the pituitary gland removed, hexarelin prevented a drop in prostacyclin release from the heart.
Peptide
Hexarelin
Outcome
IncreaseProstacyclin release
Study
ratn: not reported in source
Hypophysectomized rat, explanted heart ischemia-reperfusion
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg · subcutaneous · 7 daysAs given in this study (rat).
Source sentences
Summary
Moreover, hexarelin prevents the fall in prostacyclin release and enhances recovery of contractility.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain whether hexarelin had non-GH-mediated protective effects on the heart, we compared hexarelin and GH treatment in hypophysectomized rats.
Report a problemFND-1046527206
07AnimalAnimal study (in vivo)Efficacy outcome
In hypophysectomized rats, hexarelin enhanced recovery of heart contractility after ischemia-reperfusion.
In plain wordsIn rats with the pituitary gland removed, hexarelin improved how well the heart muscle recovered its pumping force.
Peptide
Hexarelin
Outcome
IncreaseRecovery of contractility
Study
ratn: not reported in source
Hypophysectomized rat, explanted heart ischemia-reperfusion
Outcome group
Heart function · Cardiovascular
Studied dose
80 microg/kg · subcutaneous · 7 daysAs given in this study (rat).
Source sentences
Summary
Moreover, hexarelin prevents the fall in prostacyclin release and enhances recovery of contractility.
1 context sentence(design, population, supporting numbers)
Summary · context
To ascertain whether hexarelin had non-GH-mediated protective effects on the heart, we compared hexarelin and GH treatment in hypophysectomized rats.
Report a problemFND-1046527207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.